Neptune Reports Third Quarter Results
2012年1月17日 - 10:00PM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX:NTB) today reports its consolidated financial
results for the three-month and nine-month periods ended November
30, 2011.
Three-month Ended November 30, 2011 Financial
Results
Nutraceutical Business Results
- Nutraceutical revenue increased by 20% to $5,120,000, for the
three-month period ended November 30, 2011, up from $4,272,000
achieved during the corresponding period ended November 30,
2010.
- Nutraceutical EBITDA increased to $1,081,000, for the
three-month period ended November 30, 2011, up from $425,000
achieved during the corresponding period ended November 30,
2010.
- Net income from nutraceutical business reached $869,000 for the
three-month period ended November 30, 2011, compared to a net loss
of $13,000, for the corresponding period ended November 30,
2010.
Consolidated Results
- Revenue increased by 19% to $5,124,000 for the three-month
period ended November 30, 2011, up from $4,290,000 achieved during
the corresponding period ended November 30, 2010.
- Consolidated EBITDA for the three-month period ended November
30, 2011 amounted to ($743,000), compared to ($156,000) obtained
during the corresponding period ended November 30, 2010, due to
subsidiaries significant R&D expenses.
- Net earnings decreased to a net loss of $1,433,000 for the
three-month period ended November 30, 2011, compared to a net loss
of $498,000 for the corresponding period ended November 30, 2010,
due to subsidiaries significant R&D expenses.
"We delivered strong third quarter revenue driven by outstanding
performance from the neutraceutical business of Neptune," said
Andre Godin ,CFO. "Neptune delivered a remarkable quarter thanks to
our leadership positions in North America and Europe, where we have
grown both sales and market share this year. We look forward to
this afternoon conference call, as we will give a full corporate
update to our shareholders," he added.
"We continue to build momentum as demonstrated by our solid
third quarter results. During the third quarter our long-term
strategic investments in the company's intellectual property
protection and valorization helped drive strong revenue
performance," said Frederic Harland, Director of finance. "As we
look back at the past quarters, we expect continued sales growth
driven by price and quantities and are confident in our growth
strategy and commercial plans," he added.
Nine-month Ended November 30, 2011 Financial
Results
Nutraceutical Business Results
- Nutraceutical revenue increased by 10% to $13,756,000, for the
nine-month period ended November 30, 2011, up from $12,504,000
achieved during the corresponding period ended November 30,
2010.
- EBITDA from nutraceutical business for the nine-month period
ended November 30, 2011 was $2,505,000, compared to $2,787,000
obtained during the corresponding period ended November 30,
2010.
- Net income from nutraceutical business reached $1,005,000 for
the nine-month period ended November 30, 2011, compared to a net
income of $1,996,000, for the corresponding period ended November
30, 2010.
Consolidated Results
- Revenue increased by 10% to $13,770,000 for the nine-month
period ended November 30, 2011, up from $12,566,000 achieved during
the corresponding period ended November 30, 2010.
- Consolidated EBITDA for the nine-month period ended November
30, 2011 amounted to a negative $1,818,000, compared to $1,345,000
obtained during the corresponding period ended November 30, 2010,
due to subsidiaries significant R&D expenses.
- Net earnings decreased to a net loss of $4,459,000 for the
nine-month period ended November 30, 2011, compared to a net income
of $519,000 for the corresponding period ended November 30, 2010,
due to subsidiaries significant R&D expenses.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 30
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements»
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and Canadian securities laws. Such forward-looking
statements involve known and unknown risks, uncertainties, and
other unknown factors that could cause the actual results of the
Company to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. In addition to statements which explicitly describe
such risks and uncertainties, readers are urged to consider
statements labeled with the terms "believes," "belief," "expects,"
"intends," "anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that
are described from time to time in the Company's reports filed with
the Securities and Exchange Commission and the Canadian securities
commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dave@howardgroupinc.com
www.howardgroupinc.com
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 6 2024 まで 7 2024
Neptune Wellness Solutions (NASDAQ:NEPT)
過去 株価チャート
から 7 2023 まで 7 2024